CL2017000971A1 - Composición farmacéutica para uso en el aumento del trofismo de mucosa nasal - Google Patents

Composición farmacéutica para uso en el aumento del trofismo de mucosa nasal

Info

Publication number
CL2017000971A1
CL2017000971A1 CL2017000971A CL2017000971A CL2017000971A1 CL 2017000971 A1 CL2017000971 A1 CL 2017000971A1 CL 2017000971 A CL2017000971 A CL 2017000971A CL 2017000971 A CL2017000971 A CL 2017000971A CL 2017000971 A1 CL2017000971 A1 CL 2017000971A1
Authority
CL
Chile
Prior art keywords
nasal mucosa
trophism
increasing
pharmaceutical composition
nasal
Prior art date
Application number
CL2017000971A
Other languages
English (en)
Inventor
Giorgio Panin
Domenico Testa
Germano Guerra
Original Assignee
Bio Lo Ga Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51951918&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2017000971(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bio Lo Ga Srl filed Critical Bio Lo Ga Srl
Publication of CL2017000971A1 publication Critical patent/CL2017000971A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355Tocopherols, e.g. vitamin E
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

<p>COMPOSICIÓN PARA APLICACIÓN TÓPICA, PARA USO EN EL INCREMENTO DE TROFISMO DE LA MUCOSA NASAL, QUE COMPRENDE UN ÉSTER DE VITAMINA E CON UN ÁCIDO CARBOXÍLICO DE LA FÓRMULA R-COOH, EN LA CUAL R ES UN RADICAL ALQUILO QUE TIENE 1 A 19 ÁTOMOS DE CARBONO, O UN RADICAL ALQUENILO O ALQUINILO QUE TIENE 2 A 19 ÁTOMOS DE CARBONO, Y UN VEHÍCULO ACEITOSO; ESTA COMPOSICIÓN SE PUEDE UTILIZAR PARA EL TRATAMIENTO DE RINITIS ATRÓFICA CRÓNICA Y PARA OBTENER LA REPARACIÓN DE TEJIDO DE LA MUCOSA NASAL DESPUÉS DE LA CIRUGÍA NASAL Y DE SENOS PARANASALES.</p>
CL2017000971A 2014-10-22 2017-04-20 Composición farmacéutica para uso en el aumento del trofismo de mucosa nasal CL2017000971A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITMI20141819 2014-10-22

Publications (1)

Publication Number Publication Date
CL2017000971A1 true CL2017000971A1 (es) 2018-01-12

Family

ID=51951918

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017000971A CL2017000971A1 (es) 2014-10-22 2017-04-20 Composición farmacéutica para uso en el aumento del trofismo de mucosa nasal

Country Status (20)

Country Link
US (1) US10226444B2 (es)
EP (1) EP3209294B1 (es)
CN (1) CN107438429A (es)
AU (1) AU2015335204B2 (es)
CA (1) CA2965184A1 (es)
CL (1) CL2017000971A1 (es)
CY (1) CY1122289T1 (es)
DK (1) DK3209294T3 (es)
EA (1) EA033078B1 (es)
ES (1) ES2757349T3 (es)
GE (1) GEP20186863B (es)
HR (1) HRP20191989T1 (es)
HU (1) HUE047203T2 (es)
LT (1) LT3209294T (es)
MX (1) MX2017005195A (es)
PL (1) PL3209294T3 (es)
PT (1) PT3209294T (es)
RS (1) RS59496B1 (es)
SI (1) SI3209294T1 (es)
WO (1) WO2016062522A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3026108A1 (en) 2016-06-10 2017-12-14 Clarity Cosmetics Inc. Non-comedogenic hair and scalp care formulations and method for use
IT201700047210A1 (it) * 2017-05-02 2018-11-02 St Ganassini Spa Di Ricerche Biochimiche Composizione cosmetica e/o dermatologica, e suoi usi in campo cosmetico e nel trattamento coadiuvante di patologie dermatologiche
IT201900003515A1 (it) * 2019-03-11 2020-09-11 Gilas Sas Di Carcano Maria Grazia E C COMPOSIZIONE DERMO-COSMETICA PER USO TOPICO, A BASE DI VITAMINA E e/o SUOI ESTERI

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4364945A (en) 1979-12-13 1982-12-21 Whittle Barry J Nasal composition for relieving nasal distress
US20100055152A1 (en) 2008-08-26 2010-03-04 Trutek Corporation Antihistamine and antihistamine-like nasal application, products, and method
IT1282778B1 (it) * 1996-05-31 1998-03-31 Giorgio Panin Vitamina "e" acetato quale prodotto per applicazione topica
ITMI981586A1 (it) * 1998-07-10 2000-01-10 Giorgio Panin Vitamina e e suoi esteri per l'uso nel trattamento topico di patologie delle mucose
IT1393056B1 (it) * 2008-09-22 2012-04-11 Bio Lo Ga Srl Uso di vitamina e o suoi derivati per il controllo di artropodi
US10561720B2 (en) 2011-06-24 2020-02-18 EpitoGenesis, Inc. Pharmaceutical compositions, comprising a combination of select carriers, vitamins, tannins and flavonoids as antigen-specific immuno-modulators
FR2981273B1 (fr) * 2011-10-14 2013-12-20 Gilles Andre Yves Bhat Nouvelle composition pour les muqueuses: tocopherol, macerat huileux de fleurs de calendula dans de l'huile de rose musquee, palmitate de retinol, ubiquinone, ascorbyl palmitate et lactobacillus

Also Published As

Publication number Publication date
DK3209294T3 (da) 2019-10-28
CY1122289T1 (el) 2021-01-27
BR112017008070A2 (pt) 2018-02-20
US10226444B2 (en) 2019-03-12
MX2017005195A (es) 2017-10-04
EA201790447A1 (ru) 2017-09-29
ES2757349T3 (es) 2020-04-29
SI3209294T1 (sl) 2019-12-31
WO2016062522A1 (en) 2016-04-28
AU2015335204B2 (en) 2020-10-08
CN107438429A (zh) 2017-12-05
CA2965184A1 (en) 2016-04-28
US20170290799A1 (en) 2017-10-12
BR112017008070A8 (pt) 2022-07-05
EP3209294B1 (en) 2019-08-21
EA033078B1 (ru) 2019-08-30
AU2015335204A1 (en) 2017-04-13
LT3209294T (lt) 2019-10-25
RS59496B1 (sr) 2019-12-31
EP3209294A1 (en) 2017-08-30
PT3209294T (pt) 2019-10-08
HRP20191989T1 (hr) 2020-02-07
GEP20186863B (en) 2018-06-11
PL3209294T3 (pl) 2020-01-31
HUE047203T2 (hu) 2020-04-28

Similar Documents

Publication Publication Date Title
CL2017001893A1 (es) Uso de prg4 como agente antiinflamatorio
GT201500312A (es) Derivados de sulfamoilpirrolamida y su uso como medicamentos para el tratamiento de la hepatitis b
CL2015002164A1 (es) Formulación combinada de dos compuesos antivirales.
PE20170904A1 (es) Esteroides neuroactivos, composiciones y usos de los mismos
CL2015000787A1 (es) Derivados de 1,2,4-triazina para el tratamiento de infecciones virales.
BR112015022047A2 (pt) métodos para tratar câncer de bexiga
BR112015022545A2 (pt) compostos de pirazolo e os usos disso
CL2017000533A1 (es) Pirrolopirimidinas para uso en la infección por el virus de la gripe
CR20150571A (es) Compuestos y composiciones terapéuticos
UY33885A (es) Inhibición de la il17 y del ifn-gamma para el tratamiento de las inflamaciones autoinmunes
CL2015000976A1 (es) Compuestos de 2-fenil-5-heterociclil-tetrahidro-2h-piran-3-amina para uso en el tratamiento de diabetes y sus trastornos asociados.
SV2017005466A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
BR112016012840A2 (pt) Derivado de pirimidina e fonte de ácido graxo para uso no tratamento de prisão de ventre
BR112015024332A2 (pt) sonda fluorescente para estanho
CO2019012814A2 (es) Composición farmacéutica líquida estable
BR112015022162A2 (pt) sonda fluorescente de zinco
CL2017000971A1 (es) Composición farmacéutica para uso en el aumento del trofismo de mucosa nasal
PE20142182A1 (es) Inhibidores de iap
DOP2015000176A (es) Compuestos de azetidiniloxifenilpirrolidina
CL2018001221A1 (es) Modular la expresión de apolipoproteína (a)
CL2016001098A1 (es) Uso de cisteamina y sus derivados para el tratamiento de enfermedades mitocondriales
CL2016001192A1 (es) Uso de un inhibidor de dihidroorato deshidrogenasa (dhodh) para tratar enfermedades neurodegenerativas.
CL2012003006A1 (es) Compuestos derivados de lactonas esteroideas insaturadas en la posicion 7(8) y sus sales y estereoisomeros farmaceuticamente aceptables; composicion farmaceutica que las comprende; y su uso para el tratamiento del cancer.
CL2015001446A1 (es) Procedimiento de preparación de albumina humana con nivel de oxigeno disuelto reducido.
ECSP15050273A (es) Formulación oral para el tratamiento de enfermedades cardiovasculares